Human IL-11 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB218
Conjugate
Catalog #
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
Neutralization, Western Blot
Cited:
Inhibition, Neutralization, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2A Clone # 22626
Product Specifications
Immunogen
E. coli-derived recombinant human IL-11
Pro22-Leu199
Accession # P20809
Pro22-Leu199
Accession # P20809
Specificity
Detects human IL-11 in direct ELISAs and Western blots. In direct ELISAs and Western blots, 100% cross-reactivity with recombinant mouse IL-11 is observed and no cross-reactivity with recombinant human (rh) IL-6, rhCNTF, rhLIF, rhOSM, rhCLC, or rhCT-1 is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IL-11 Antibody
Cell Proliferation Induced by IL-11 and Neutralization by Human IL-11 Antibody.
Recombinant Human IL-11 (Catalog # 218-IL) stimulates proliferation in the T11 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL-11 (1 ng/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-Human IL-11 Monoclonal Antibody (Catalog # MAB218). The ND50 is typically ≤ 8 µg/mL.Detection of Human IL-11 by Western Blot
Autocrine IL-6 activates STAT3 signalling in lung cancer cell-induced epidural ADSCs. a Epidural ADSCs were pre-treated with CM from lung cancer cells for 48 h, and pSTAT3 and STAT3 expression levels were detected by western blotting. Epidural ADSCs cultured in untreated medium served as a control. b The effects of lung cancer cell CM on epidural ADSC proliferation were evaluated using the CCK-8 assay. Epidural ADSCs were treated with CM from one of four lung cancer cell lines, and the optical density of both groups at 450 nm was analysed. Data from three separate experiments are shown. c Western blot analysis of pSTAT3 and STAT3 in epidural ADSCs treated with either 10 ng/mL recombinant IL-6, 10 ng/mL recombinant IL-11 or 50 ng/mL recombinant LIF in the presence or absence of either neutralizing antibodies or isotype controls. Loading control, actin. d Western blot analysis of pSTAT3 and alpha-SMA expression in epidural ADSCs treated with lung cancer cell CM in the presence or absence of neutralizing antibodies against IL-6, IL-11 or LIF. Loading control, actin. *P < 0.05; **P < 0.01; ***P < 0.001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31196220), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Human IL-11 by Western Blot
Autocrine IL-6 activates STAT3 signalling in lung cancer cell-induced epidural ADSCs. a Epidural ADSCs were pre-treated with CM from lung cancer cells for 48 h, and pSTAT3 and STAT3 expression levels were detected by western blotting. Epidural ADSCs cultured in untreated medium served as a control. b The effects of lung cancer cell CM on epidural ADSC proliferation were evaluated using the CCK-8 assay. Epidural ADSCs were treated with CM from one of four lung cancer cell lines, and the optical density of both groups at 450 nm was analysed. Data from three separate experiments are shown. c Western blot analysis of pSTAT3 and STAT3 in epidural ADSCs treated with either 10 ng/mL recombinant IL-6, 10 ng/mL recombinant IL-11 or 50 ng/mL recombinant LIF in the presence or absence of either neutralizing antibodies or isotype controls. Loading control, actin. d Western blot analysis of pSTAT3 and alpha-SMA expression in epidural ADSCs treated with lung cancer cell CM in the presence or absence of neutralizing antibodies against IL-6, IL-11 or LIF. Loading control, actin. *P < 0.05; **P < 0.01; ***P < 0.001 Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31196220), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human IL-11 Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: Recombinant Human IL-11 (Catalog # 218-IL)
Sample: Recombinant Human IL-11 (Catalog # 218-IL)
Neutralization
Measured by its ability to neutralize IL‑11-induced proliferation in the T11 mouse plasmacytoma cell line. Nordan, R. P. et al. (1987) J. Immunol. 139:813. The Neutralization Dose (ND50) is typically ≤ 8 µg/mL in the presence of 1 ng/mL Recombinant Human IL‑11.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 2 reviews rated 5 using MAB218 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-11
Long Name
Interleukin 11
Alternate Names
AGIF, IL11, Oprelvekin
Gene Symbol
IL11
UniProt
Additional IL-11 Products
Product Documents for Human IL-11 Antibody
Product Specific Notices for Human IL-11 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...